EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient Perspectives on Treatment Outcomes and Priorities in Autoimmune Bullous Diseases: An Exploratory Survey among Dutch Patients

Marjolein A J Hiel, Eva W H Korte, Maria C Bolling, Joost M Meijer, Barbara Horváth

Dermatology · 29.04.2026 · 1-10

DOI: 10.1159/000552182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatology, online erschienen am 29.04.2026. Verfasst von Marjolein A J Hiel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), University Medi…. Hauptthemen laut MEDLINE: Patient Reported Outcome Measures, Pemphigus, Skin Diseases, Vesiculobullous, Autoimmune Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Autoimmune bullous diseases (AIBDs), comprising pemphigoid and pemphigus diseases, have seen limited therapeutic advances beyond rituximab for pemphigus vulgaris. As novel therapies are evaluated in clinical trials, well-defined, uniform, and relevant outcomes with patient involvement are essential. To date, however, patient-reported outcomes remain underrepresented, leaving uncertainty about whether trial results genuinely reflect patients’ expectations. This study examines perspectives of patients with AIBD on treatment outcomes and priorities to ensure that future research focuses on what matters most to them.

Methods

A cross-sectional study was conducted among Dutch patients with AIBD between October 2023 and January 2024, using a self-developed questionnaire with both closed- and open-ended questions to assess patient perspectives on treatment outcomes and priorities, key factors in choosing a treatment, and indicators of treatment success.

Results

Regarding skin and/or mucous membrane complaints, “the formation of new blisters and wounds” emerged as the most important complaint a treatment should address for both pemphigoid (43%) and pemphigus (86%) patients. In open-ended questions, patients with pemphigoid most frequently prioritized “pruritus” (44%), while patients with pemphigus emphasized “pain” (39%). Most important concerns regarding physical and daily functioning were “vision problems” (20%), “sleep disturbances” (20%), and “self-care difficulties” (23%) for patients with pemphigoid, whereas patients with pemphigus most commonly cited “eating and/or swallowing difficulties” (57%) and “daily activity limitations” (41%). Regarding emotional/psychological functioning, both subgroups prioritized “anxiety and/or worry” as most important concern (pemphigoid: 28%, pemphigus: 43%). Side effects were identified as the most important factor in choosing a treatment (pemphigoid: 41%, pemphigus: 39%). The absence of one or more symptoms and clinical signs (i.e., “no blisters”) was mentioned as the most important indicator of treatment success (pemphigoid: 88%, pemphigus: 91%), although minimal clinical signs (i.e., “minimal blisters”) were also considered acceptable (pemphigoid: 25%, pemphigus: 13%).

Conclusion

Patients with pemphigoid and pemphigus exhibit some distinct treatment priorities, reflecting their distinct pathomechanisms. Nonetheless, both subgroups consistently prioritize not only the resolution of disease-specific clinical signs but also preservation of physical and psychological well-being, underscoring the need for more holistic and patient-centered outcome measurement to ensure the establishment of meaningful, AIBD subgroup specific treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient Reported Outcome MeasuresPemphigusSkin Diseases, VesiculobullousAutoimmune DiseasesPemphigoid, BullousHumansCross-Sectional StudiesMaleFemaleNetherlandsAgedMiddle AgedTreatment OutcomeAdultSurveys and QuestionnairesAged, 80 and over

Stichwörter der Autor:innen

Autoimmune bullous diseaseImmunobullous diseasePatient perspectivesTreatment outcomesTreatment priorities

Autor:innen und Institutionen

  • Department of Dermatology, Center of Expertise for Blistering Diseases, European Reference Network for Rare Skin Diseases (ERN SKIN), University Medical Center Groningen, University of Groningen, Groningen, The Netherla…

Zitieren

APA

Hiel, M. A. J., Korte, E. W. H., Bolling, M. C., Meijer, J. M., & Horváth, B. (2026). Patient Perspectives on Treatment Outcomes and Priorities in Autoimmune Bullous Diseases: An Exploratory Survey among Dutch Patients. Dermatology, 1-10. https://doi.org/10.1159/000552182

Vancouver

Hiel MAJ, Korte EWH, Bolling MC, Meijer JM, Horváth B. Patient Perspectives on Treatment Outcomes and Priorities in Autoimmune Bullous Diseases: An Exploratory Survey among Dutch Patients. Dermatology. 2026:1-10. doi:10.1159/000552182

BibTeX
@article{Hiel2026,
  author = {Hiel, Marjolein A J and Korte, Eva W H and Bolling, Maria C and Meijer, Joost M and Horváth, Barbara},
  title = {Patient Perspectives on Treatment Outcomes and Priorities in Autoimmune Bullous Diseases: An Exploratory Survey among Dutch Patients},
  journal = {Dermatology},
  year = {2026},
  pages = {1--10},
  doi = {10.1159/000552182}
}
Kostenlos starten →